Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
THLD > SEC Filings for THLD > Form 8-K on 15-Mar-2013All Recent SEC Filings

Show all filings for THRESHOLD PHARMACEUTICALS INC | Request a Trial to NEW EDGAR Online Pro

Form 8-K for THRESHOLD PHARMACEUTICALS INC


15-Mar-2013

Change in Directors or Principal Officers


Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 13, 2013, the Board of Directors of the Company (the "Board"), upon recommendation of the Compensation Committee, approved the following base salary increases, effective January 1, 2013: Tillman E. Pearce, Chief Medical Officer -$361,000 Stewart M. Kroll, Senior Vice President of Biostatistics and Clinical Operations -$320,000, Mark D. Matteucci, Senior Vice President, Discovery Research-$310,000, and Joel Fernandes, Vice President, Finance and Controller-$263,000.

Also on March 13, 2013, the Board, upon recommendation of the Compensation Committee, approved the following bonuses for services rendered to the Company during the fiscal year ended December 31, 2012: Harold E. Selick, the Company's Chief Executive Officer -$287,500 (acted on and approved solely by the independent members of the Board), Dr. Pearce-$104,508, Mr. Kroll -$106,459, Dr. Matteucci -$101,351, and Mr. Fernandes-$76,257.

Also on March 13, 2013, the Board, based upon the recommendation of the Compensation Committee, granted an incentive stock option to each of the Company's executive officers under the Company's 2004 Amended and Restated Equity Incentive Plan (the "Plan"), which was filed as Exhibit 10.2 to the Company's annual report on Form 10-K, filed with the Securities and Exchange Commission on March 15, 2012. Each option is exercisable for the following number of shares of the Company's common stock ("Common Stock"): Dr. Selick - 360,000 shares, Dr. Pearce -140,000 shares, Mr. Kroll -100,000 shares, Dr. Matteucci -115,000 shares, and Mr. Fernandes-90,000 shares. Each of these options has a term of 10 years and a vesting commencement date of March 13, 2013. The shares of Common Stock subject to each option will vest as to 1/48th of the shares on a monthly basis such that the options are 100% vested as of March 13, 2017, assuming the executive officer continues to remain an employee of the Company. The exercise price per share for each option is $5.09 per share, the closing sales price of the Company's Common Stock on the NASDAQ Capital Market on the date of grant.

Also on March 13, 2013, the Board, based upon the recommendation of the Compensation Committee, approved increasing the annual retainer for members of the Audit Committee by $1,000 to $11,000 and increasing the annual retainer for the chair of the Audit Committee by $2,750 to $18,750.

  Add THLD to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for THLD - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now


Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.